Analyzing Upward Deviation of Actual vs Predicted Drug Sales in Japan for a Reasonable Drug-Pricing Policy.


BACKGROUND:Predictions of drug sales play an important role in setting drug prices in Japan, where drug prices are highly regulated. One of 2 primary Japanese drug-pricing methodologies-the cost calculation method- refers extensively to the prediction of drug sales in establishing drug prices. Deviations from predicted sales can induce disproportionate drug prices and unexpected pharmaceutical expenditures. This study aimed to estimate the upward deviation of actual sales from predicted sales and to explore the predictors of such upward deviation. METHODS:Estimates of upward deviation in 2015 were produced for new molecular entities (NMEs) approved in 2006-2015. To identify the predictors associated with upward deviation through binary logistic regression analyses, sales within 3 years of launch and in the predicted year in which peak sales would be reached were used. RESULTS:Estimated upward deviation was more than 1220 billion yen in 2015 for the targeted drugs. Drugs priced by the cost calculation method or by obtaining additional indications were significantly more likely to show an upward deviation from predicted peak sales. CONCLUSION:There is substantial upward deviation between actual and predicted drug sales in Japan. So long as drug sales predictions are used in drug price calculations, a flexible repricing system is needed to buffer unexpected pharmaceutical expenditures.


Ther Innov Regul Sci


Shibata S,Fukumoto D,Suzuki T,Ozaki K




Has Abstract


2019-07-16 00:00:00








  • Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.

    abstract:BACKGROUND:In the breakthrough therapy designation (BTD) and Sakigake designation programs, rolling submission and close communication between applicants and regulatory authorities enable the timely access of patients to innovative medicines. However, challenges in the quality development, including chemistry, manufact...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Kajiwara E,Shikano M

    更新日期:2020-07-01 00:00:00

  • A Multifaceted Perspective of Pharmaceutical Innovation: A Consideration of the Regulatory Role.

    abstract:BACKGROUND:The pace of innovation, the creative engine of the pharmaceutical industry, has been variably described as stagnant, stable, or accelerating depending on the metric used for assessment or the quality of evidence. If the predominant perception holds that the speed of innovation is sluggish, pressure for chang...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Robberson M,Breder CD

    更新日期:2020-08-31 00:00:00

  • Smart Program Design Through a Common Information Model.

    abstract::Although much information is already available publically from information-sharing initiatives such as, information about clinical programs is unstructured, inconsistent, and incomplete. Clinical research within bioscience companies, health care, academia, and governmental agencies could benefit fro...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Vasko L,Sundgren M,Bachmann P,Balinski K,Bleich N,Blom T,Eriksson H,Ferendo R,Forsberg K,King D,Mordiva A,Proeve J,Thomas L,Witch E,Simán M

    更新日期:2015-01-01 00:00:00

  • A Conditional Adaptive Weighted Test Method for Confirmatory Trials.

    abstract::The authors consider a statistically valid method that has little concern caused by down weighting in stage 2 or slight loss in efficiency and possibly improves power performance for a trial design that allows for adaptation of statistical information. In addition to the need for a priori sound data-based planning tha...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Wang SJ,Hung HMJ

    更新日期:2014-01-01 00:00:00

  • Over-the-Counter Drugs: Regulatory Analysis of Warning Letters Between Fiscal Years 2015-2019.

    abstract:BACKGROUND:According to 21 Code of Federal Regulation (CFR) Part 211, Over-the-Counter (OTC) drug manufacturers must establish and follow current good manufacturing practices (cGMP) to produce quality products while meeting regulatory standards. The warning letters issued by the U.S. Food and Drug Administration (FDA) ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Bai HK,Ahearn JD,Bartlett MG

    更新日期:2020-10-23 00:00:00

  • Characteristics of Drug Intervention Clinical Trials and Scientific Impact of the Trial Outcome: A Bibliometric Analysis Using the Relative Citation Ratio in Non-small Cell Lung Cancer from 2007 to 2016.

    abstract:BACKGROUND:Although a large number of clinical trials have been conducted, the types of clinical trials that are scientifically influential, frequently utilized by society, and contribute to the progress of evidence-based medicine (EBM) have not been studied. Thus, we aimed to investigate the relationship between the c...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Noguchi Y,Kaneko M,Narukawa M

    更新日期:2020-11-01 00:00:00

  • The Competence and Willingness to Consent to Research Among Patients with Heroin Dependence.

    abstract:BACKGROUND:Substance abuse research can raise ethical concerns about the comprehension and decision-making capacities of participants with drug dependence. In this study, the competence and willingness to consent to research participation were examined among patients with heroin dependence. METHODS:Twenty patients wit...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Zhao L,Shi H,Ying B,Li Q

    更新日期:2020-09-01 00:00:00

  • Product Registration in Developing Countries: A Proposal for an Integrated Regional Licensing System Among Countries in Regional Economic Blocs.

    abstract::The product pipeline for diseases that disproportionately affect the developing world has considerably expanded over the last decade. Indeed, there are about 134 products for these diseases in the pipeline, including vaccines, drugs, diagnostics, microbicides, and vector control tools, and dozens of these products are...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Saidu Y,De Angelis D,Aiolli S,Stefano G,Georges AM

    更新日期:2013-05-01 00:00:00

  • Labeling Standards for Biosimilar Products.

    abstract::In 2010 Congress established a regulatory pathway for the approval of biosimilar products in the United States. FDA has embarked on developing the implementation framework for this pathway which includes creating guidance to assist biosimilar manufacturers in the development of these products. However, to date, the gu...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Davis GC,Bowker GM

    更新日期:2014-05-01 00:00:00

  • A Framework for Managing the Minimal Clinically Important Difference in Clinical Trials.

    abstract::There is a long history of discussions about what is a minimal clinically important difference (MCID) and how this term applies to clinical research. This paper deals with a practical framework for MCID and its applicability to clinical trials. A literature review on the topic confirmed the fundamental role of MCID fo...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Koynova D,Lühmann R,Fischer R

    更新日期:2013-07-01 00:00:00

  • A Practical Estimation Method for Analyzing Adverse Drug Reactions Using Data Mining.

    abstract::This study aimed to determine the potentially severe chemical properties of drugs that can cause adverse drug reactions (ADRs) such as erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) by using a data mining method. The study data were extracted from the Adverse Event Repor...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Shirakuni Y,Okamoto K,Uejima E,Inui S,Takahara JI,Ohgaru T,Yamasaki H,Tian Y,Kawashita N,Inoue R,Yasunaga T,Takagi T

    更新日期:2013-03-01 00:00:00

  • Bowel Preparations for Colonoscopy: A Regulatory Perspective.

    abstract::Agents indicated for cleansing of the colon as a preparation for colonoscopy (bowel preps) are among the most frequently prescribed drugs for otherwise healthy patients. Better bowel preparation has been shown to translate into higher adenoma detection rates. Therefore, safety and efficacy standards need to be high. C...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Gottlieb K,Turner JR,Gillespie BS,Hussain F

    更新日期:2015-09-01 00:00:00

  • Industry and Patient Perspectives on Child Participation in Clinical Trials: The Pediatric Assent Initiative Survey Report.

    abstract:BACKGROUND:Obtaining assent from children participating in clinical trials acknowledges autonomy and developmental ability to contribute to the consent process. This critical step in pediatric drug development remains poorly understood, with significant room for improving the clarity, efficiency, and implementation of ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Lombardi D,Squires L,Sjostedt P,Eichler I,Turner MA,Thompson C

    更新日期:2018-01-01 00:00:00

  • Evaluation and Characterization of Health Economics and Outcomes Research in SAARC Nations.

    abstract:OBJECTIVE:To identify, evaluate, and characterize the variety, quality, and intent of the health economics and outcomes research studies being conducted in SAARC (South Asian Association for Regional Cooperation) nations. METHODS:Studies published in English language between 1990 and 2015 were retrieved from Medline d...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审


    authors: Mehta M,Nerurkar R

    更新日期:2018-05-01 00:00:00

  • Strategic Shift of Statistical Review on Data Quality Assessment for New Drug Applications in China.

    abstract::Data quality is critical for clinical trials to obtain robust conclusions about drug safety and efficacy evaluation. Effective data quality evaluation has been one of the major obstacles to new drug approvals in China, which hinders innovation in drug discovery and development ultimately. To improve the data quality s...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Wang J,Wang G,Li M,Han J,Zeng X,Pan J,Yang J

    更新日期:2019-03-01 00:00:00

  • How FDA Advisory Committee Members Prepare and What Influences Them.

    abstract::Since 1992 many changes have occurred in the regulations, guidelines, and processes governing the FDA, the biomedical industry, other stakeholders, and their interactions. Of particular importance, the FDA Amendments Act of 2007 made public advisory committee meetings mandatory for new molecular entities and devices r...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: McIntyre TD,Pappas M,DiBiasi JJ

    更新日期:2013-01-01 00:00:00

  • An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.

    abstract:BACKGROUND:This study compared the timing, regulatory marketing authorization decisions, and the final labeling for products submitted to Swissmedic to those submitted to European Medicines Agency (EMA) and the US Food & Drug Administration (FDA). METHODS:The Centre for Innovation in Regulatory Science (CIRS) conducte...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Dörr P,Wadworth A,Wang T,McAuslane N,Liberti L

    更新日期:2016-11-01 00:00:00

  • Regulatory Definitions and Good Pharmacovigilance Practices in Social Media: Challenges and Recommendations.

    abstract::Social media presents new challenges to the biopharmaceutical industry for conducting pharmacovigilance activities. The authors reviewed worldwide regulatory guidance documents related to monitoring of adverse events posted on social media sites and identified gaps in current regulatory definitions for pharmacovigilan...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Naik P,Umrath T,van Stekelenborg J,Ruben R,Abdul-Karim N,Boland R,Ibara M,Ekuta J,Washburn D,Stergiopoulos S

    更新日期:2015-11-01 00:00:00

  • Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients' Access to Medicines.

    abstract:BACKGROUND:Timely access to new medicines may be addressed through strengthening of registration efficiencies and timelines by establishing and refining value-added registration processes, resources, and systems. The aims of this study were to evaluate the timelines of the milestones of the South African review process...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Keyter A,Salek S,Gouws J,Banoo S,Walker S

    更新日期:2020-07-01 00:00:00

  • Investigating Rates of Food and Drug Administration Approvals and Guidances in Drug Development: A Structural Breakpoint/Cointegration Timeseries Analysis.

    abstract:BACKGROUND:The number of original and supplemental ANDAs, BLAs, NDAs, and Biosimilars FDA drug/biologic approvals (Approvals) has risen dramatically in the recent years, incidentally, so has the number of issued FDA guidances (Guidances). It is hypothesized that if the structures of the two timeseries are similar and/o...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Daizadeh I

    更新日期:2020-09-01 00:00:00

  • Improving Drug Development and Patient Access With the Right People, Processes, and Culture: What Needs to Happen Right Now to Bring Better Medicines to the Patients Who Need Them.

    abstract::In a global environment where health care costs are soaring, R&D efforts are flatlining. Meanwhile, payers are demanding more value for their money. In this environment, the traditional siloed drug development model is not sustainable. Yet innovations such as adaptive trial designs, real-world data collection, precisi...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Grignolo A,Siu A

    更新日期:2019-05-01 00:00:00

  • An Overview and Analysis Regarding the Use of Adjudication Methods in EU and US Drug Approvals.

    abstract:BACKGROUND:Several regulatory guidelines recommend that assessments of endpoints supporting drug approval should be verifiable by applicants and the regulatory agencies to minimize the potential for bias. This becomes especially critical when assessments are not based on measurable data but are derived from the interpr...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Krumholz-Bahner S,Garibbo M,Getz KA,Widler BE

    更新日期:2015-11-01 00:00:00

  • Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA's Benefit-Risk Framework to Calculate Net-Benefit Score and Benefit-Risk Ratio.

    abstract:BACKGROUND:Approval of regulated medical products in the USA is based upon a rigorous review of the benefits and risks as performed by the US Food and Drug Administration (FDA) staff of scientists and is summarized in a descriptive and qualitative format called the FDA's Benefit-Risk Framework (BRF). This present metho...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Sun S,Heske S,Mercadel M,Wimmer J

    更新日期:2021-01-01 00:00:00

  • Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation.

    abstract::After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the guidance of the European Medicines Agency in 2014. Althoug...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Schulthess D,Baird LG,Trusheim M,Unger TF,Lumpkin M,Hoos A,Garner S,Gavin P,Goldman M,Seigneuret N,Chlebus M,Van Baelen K,Bergstrom R,Hirsch G

    更新日期:2016-05-01 00:00:00

  • Risk Evaluation and Mitigation Strategies With Elements to Assure Safe Use: Alignment of the Goals With the Tools to Manage Risk.

    abstract::The Food and Drug Administration Amendments Act of 2007 gave the FDA the authority to require drug sponsors to submit a risk evaluation and mitigation strategies (REMS) program for those medicines with serious risks such that failure to effectively manage these risks would tip the benefit-risk balance. As of August 8,...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Cronin M,Berger S,Seligman PJ

    更新日期:2014-11-01 00:00:00

  • Rheumatoid Arthritis Disease Progression Modeling.

    abstract::Time progression models provide a significant advantage in developing clinical trials and can also be used to elicit comparisons among therapeutic agents. The authors performed a meta-analysis to construct a time progression model for rheumatoid arthritis (RA), an area of significant interest for pharmaceutical develo...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Reeve R,Pang L,Ferguson B,O'Kelly M,Berry S,Xiao W

    更新日期:2013-11-01 00:00:00

  • Assessing the Quality of Database Search Strategies Utilized by Meta-analyses That Evaluate Infectious Disease Drug Therapy.

    abstract::Meta-analyses are increasingly influencing clinical practice, but significant methodological flaws have been reported. The purpose of this study was to evaluate the quality of search strategies utilized by anti-infective meta-analyses. The Embase database was searched for meta-analyses evaluating anti-infective drug t...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Marler JL,Curry KY,Suda KJ

    更新日期:2014-05-01 00:00:00

  • Comparative Assessment of Non-trial Access to Investigational Medical Products in the U.S. and Japan.

    abstract::The U.S. and Japan have preapproval access systems for patients who have exhausted approved treatment options. We compare the systems of both countries and discuss some ethical concerns surrounding non-trial access to investigational drugs. Notable points of comparison of the two countries' systems include cost of non...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Nakada H,Folkers KM,Takashima K

    更新日期:2020-10-23 00:00:00

  • Regulatory Trends in Drug Development in Asia Pacific.

    abstract::The Asia Pacific (AP) region is diverse and dynamic. It comprises over 40 economies, with about 24 markets that are relatively more active in terms of promulgating and implementing regulations that impact the biopharmaceutical industry and advance drug development. Although many country- and territory-specific regulat...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: Han FV,Weiss K

    更新日期:2019-07-01 00:00:00

  • Building a Better Approach for the Benefit of Patients: 10 Pillars to Strengthen Regulatory Review Systems Globally.

    abstract::In the current pharmaceutical regulatory environment, patients continue to benefit from great advances in medical care. Sophisticated regulatory review systems have also evolved to ensure that safe and effective medicines are approved. However, these systems are not optimized in all countries. Gaps in individual regul...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章


    authors: O'Brien J,Lumsden RS,Diehl DH,Macdonald JC

    更新日期:2020-03-01 00:00:00